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Abstract
Background: 3,4-Methylenedioxymethamphetamine (MDMA or “ecstasy”) is a worldwide drug of abuse commonly
used by adolescents. Most reports focus on MDMA’s neurotoxicity and use high doses in adult animals, meanwhile
studies in adolescents are scarce. We aimed to assess in rats the acute MDMA toxicity to the brain and peripheral
organs using a binge dose scheme that tries to simulate human adolescent abuse.
Methods: Adolescent rats (postnatal day 40) received three 5 mg/kg doses of MDMA (estimated equivalent to
two/three pills in a 50 kg adolescent), intraperitoneally, every 2 h, while controls received saline. After 24 h animal
sacrifice took place and collection of brain areas (cerebellum, hippocampus, frontal cortex and striatum) and
peripheral organs (liver, heart and kidneys) occurred.
Results: Significant hyperthermia was observed after the second and third MDMA doses, with mean increases of
1 °C as it occurs in the human scenario. MDMA promoted ATP levels fall in the frontal cortex. No brain oxidative
stress-related changes were observed after MDMA. MDMA-treated rat organs revealed significant histological
tissue alterations including vascular congestion, but no signs of apoptosis or necrosis were found, which was
corroborated by the lack of changes in plasma biomarkers and tissue caspases. In peripheral organs, MDMA did not
affect significantly protein carbonylation, glutathione, or ATP levels, but liver presented a higher vulnerability as
MDMA promoted an increase in quinoprotein levels.
Conclusions: Adolescent rats exposed to a moderate MDMA dose, presented hyperthermia and acute tissue
damage to peripheral organs without signs of brain oxidative stress.
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Background
Over the past decades, amphetamine-type psychostimu-
lants, such as 3,4-methylenedioxymethamphetamine
(MDMA, “ecstasy”) became widely used as recreational
drugs by adolescents and young people around the
world [1, 2]. According to the United Nations Office of
Drugs and Crime, the estimated global users of MDMA
ranged from 9.4 to 28.2 million in 2012 [3]. In Europe,
2.0 of the 2.5 million past-year “ecstasy” users in 2010
were estimated to be 15–34 years old; and, in the United
States of America, 2.5 of the estimated 2.6 million people
who had used MDMA in the past year were aged from 14
to 34 years [3]. Recreational use of MDMA is frequently
done by binge administration that is a pattern of several
administrations over a short time period [4–6].
MDMA is a drug frequently used by adolescents and
therefore we need to understand the consequences of
MDMA exposure at this age through the administration
of doses and schemes more close to the human situ-
ation. Interestingly, the vast majority of studies tend
to use adult animals for studying MDMA toxicity. One
reason for this might be that the majority of studies
focus on MDMA’s neurotoxicity and neurotoxic effects
seem to be less severe in younger animals when
compared to adult animals [2]. MDMA administration
* Correspondence: armandatgomes@gmail.com; joaocapela@ff.up.pt
1UCIBIO-REQUIMTE (Rede de Química e Tecnologia), Laboratório de
Toxicologia, Departamento de Ciências Biológicas, Faculdade de Farmácia,
Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto,
Portugal
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Teixeira-Gomes et al. BMC Pharmacology and Toxicology  (2016) 17:28 
DOI 10.1186/s40360-016-0070-0
to adult laboratory animals was shown to promote long-
term depletion of monoamine neurotransmitter content,
damage to the nerve terminals, neuronal cell death and
long-lasting cognitive impairments [1, 2]. Notably, stud-
ies conducted with adolescent animals have shown that
MDMA exposure to neurotoxic doses leads to deficits in
the serotonergic system [2] and also late changes in
memory and learning abilities [7, 8]. Investigation on
adolescent laboratory animals is of extreme importance,
given that studies with human adolescents have ethical
barriers, making extremely difficult to enrol this popula-
tion in studies that evaluate drug abuse toxicity. None-
theless, studies with young adults reported deficits in
the serotonergic system [9, 10], decreased grey matter
concentration [11] and cognitive deficits [12, 13] follow-
ing MDMA abuse.
In order to produce neurotoxicity in laboratory ani-
mals’ researchers need a certain dose of MDMA, as
neurotoxicity was shown to be dose-dependent [1, 2].
MDMA neurotoxic doses in rats generally range from
20 to 40 mg/kg on a session of exposure, but the cumu-
lative dose can be much higher when treatments take
place through several days [1]. These high doses, while
important for studying neurotoxic related events, do not
match the typical MDMA user profile, as they tend to
be extremely high and correlate only to a high-intensity
abuser. One can try to extrapolate the dose used in ani-
mals to the equivalent in humans using the allometric
scaling principles, for instance: Human dose (mg/kg) =
animal dose (mg/kg) × (animal weight/human weight)1/4
[14]. This method does not account for the differences
in MDMA metabolism or administration route between
humans and rats, but is certainly of great value for an
approximate extrapolation. According to this relation a
dose of 40 mg/kg in adult rats, used in a daily session, is
equivalent to approximately 700 mg in a human with
70 kg. According to the latest European Union report
MDMA pills range from 57 to 102 mg [15], and there-
fore that dose would mean an average intake of more
than seven pills in a single session, a rather extreme sce-
nario. The binge dosing pattern that we selected for this
study [three times 5 mg/kg MDMA, intraperitoneal
(i.p.), every 2 h] was reported to promote long-term se-
rotonergic neurotoxicity in adult Wistar rats (10 week
old) [16]. We have conducted experiments that proved
that this MDMA regimen did not induce serotonergic
toxicity 7 days following MDMA administration to ado-
lescent (PND 40) Wistar rats, as no 5-HT depletion
could be found in any of the four brain areas evaluated
(manuscript being prepared for submission). Using the
mentioned formula based on allometric scaling princi-
ples, we estimate that a cumulative MDMA dose of
15 mg/kg in adolescent rats is estimated to be equivalent
in a 50 kg human adolescent to 170 mg. “Ecstasy” typical
abusers generally take more than one tablet per session,
ranging from two to four tablets in accordance with the
binge-dosing pattern [5, 6]. Therefore, and in accordance
with the last European Union report on drugs, we esti-
mate that the dose used in our protocol is equivalent to
the intake of two to three pills by adolescents using the
binge-dosing pattern. Accordingly, the current paradigm
of exposure to adolescent animals tries to mimic the
dose schedule used by human adolescents. For that rea-
son studies using more moderate doses that closely
match the typical MDMA user are needed.
The majority of studies focus on MDMA’s neurotox-
icity and neglect the toxicity of this drug to the periph-
eral organs. In vivo and in vitro studies reported
decreases in adenosine 5′-triphosphate (ATP) [17–19]
and in glutathione levels [20–22], as well as increases in
protein carbonylation [23] in the peripheral organs fol-
lowing exposure to MDMA or its metabolites. Addition-
ally, MDMA abuse was associated with histopathological
evidences of toxicity to the liver, heart and kidneys in
humans [24, 25]. Most studies that evaluate human “ec-
stasy” toxicity to peripheral organs are conducted fol-
lowing fatal outcomes or after admission to emergency
rooms. Studies are lacking regarding the evaluation of
MDMA-induced damage to organs following lower
doses. Moreover, at this point, studies in adolescent ani-
mal models regarding peripheral toxicity using moderate
MDMA doses have not been done.
In our study, we aimed to investigate MDMA toxic ef-
fects to the brain and peripheral organs in an adolescent
rat, using a moderate dose by binge administration of
MDMA, which mimics better the dose schedule of “ec-
stasy” users. To the best of our knowledge, this is the
first study in an adolescent rat model to evaluate simul-
taneously in three peripheral organs oxidative stress pa-
rameters and histological damage.
Methods
Materials
Folin–Ciocalteu reagent, cupper (II) sulphate, dimethyl
sulfoxide, disodium phosphate, ethylenediaminetetraace-
tic acid (EDTA), perchloric acid, potassium bicarbonate
(KHCO3), sodium hydroxide, sodium carbonate, magne-
sium chloride, potassium dihydrogen phosphate and
magnesium sulphate were purchased from Merck
(Darmstadt, Germany). Potassium sodium tartrate was
purchased from Fluka (Buchs SG, Switzerland), and so-
dium phosphate monobasic from Panreac (Barcelona,
Spain). Phosphate buffered saline solution (PBS) was
obtained from Biochrom (Berlin, Germany). From VWR
(Leuven, Belgium) was purchased sodium dodecyl
sulphate and sodium chloride (NaCl). Meanwhile, 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES),
xylene and methanol were obtained from Fisher Scientific
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(Loughborough, UK). Isoflurane (Isoflo®) was purchased
from Abbott (IL, USA). Lidocaine 25 mg/g + Prilocaine
25 mg/g (EMLA®) was acquired from AstraZeneca
(London, UK). The fluorescent peptide substrates for the
caspase activity assays were acquired from Peptanova
(Sandhausen, Germany). For western blot, dinitropenhyl-
KLH rabbit IgG antibody was purchased from Invitrogen/
Life Technologies (NY, USA), meanwhile 0.45 μm
Amersham Protran nitrocellulose blotting membrane and
horseradish peroxidase (HRP) conjugated anti-rabbit
antibody were acquired from GE Healthcare Bio-Sciences
(PA, USA). Histofluid was purchased from Marienfeld
(Lauda-Königshofen, Germany), Harris hematoxylin was
obtained at Harris Surgipath (IL, USA), and eosin 1 % so-
lution from Biostain (Traralgon, Australia). From Bio-Rad
Laboratories (CA, USA) was acquired the Bio-Rad DC
protein assay kit and the Clarity Western ECL reagent. All
the other reagents used were purchased from Sigma-
Aldrich (MO, USA). MDMA (HCl salt) was extracted and
purified from MDMA tablets, which were high in purity,
and were kindly provided by the Portuguese Criminal Po-
lice Department. As we have previously detailed, the ex-
tracted salt was fully characterized by mass spectrometry
and nuclear magnetic resonance, yielding a high degree of
purity that was superior to 95 % [26].
Animals
Fourteen adolescent male Wistar rats at postnatal day
(PND) 40 and weighing in average 115 ± 11 g were born
at the Institute for Biomedical Sciences Abel Salazar-
University of Porto (ICBAS-UP) animal facilities.
Animals were housed in a controlled environment
[temperature of 22.0 ± 2.0 °C, 40 % humidity and
12 hours (h) light/dark cycles]. Animals had ad libitum
access to food and water and throughout the experimen-
tal period had permanent veterinary supervision.
All procedures were performed as to give the proper
animal care, to reduce suffering and stress. Experimental
animal procedures were in agreement with the European
Council Directive (2010/63/EU) guidelines that where
transposed into Portuguese law (Decreto-Lei n.° 113/
2013, de 7 de Agosto). Additionally, the experiments
were conducted with the approval of the Ethical Com-
mittee of the Faculty of Pharmacy, University of Porto
(process n° 17/03/2014) and approved by the Portuguese
National Authority for Animal Health (General Direc-
tory of Veterinary Medicine) (process n° 0421/000/000/
2015).
Experimental protocol
Three days before the experiment, the dorsocervical
region was trichotomised and a local anaesthetic (Lido-
caine 25 mg/g + Prilocaine 25 mg/g) was allowed to act
for about 60 minutes (min). Then each animal was
subjected to a brief inhalatory anaesthesia with isoflur-
ane to perform a subcutaneous insertion of a
temperature transponder (BioMedic Data Systems Inc)
with minimum animal discomfort. This transponder en-
sures precise core body temperature measurements
throughout the entire experimental period, as we re-
ported before [27]. Prior to MDMA administration, ani-
mals were maintained in groups allowing conspecific
social interactions. In the administration day and for the
next 24 h, animals were housed individually.
Animals were randomly assigned to the two experi-
mental groups: control (n = 7) and MDMA-treated (n =
7). We selected this sample size per group based on a
pilot study that we performed. Additionally, seven ani-
mals per treatment allow the mathematical detection of
differences among means of two standard deviations (as-
suming a 5 % significance level in a t-test and a 90 %
power) [28]. For a full explanation on these statistical
calculations please see reference [28]. Additionally, sam-
ple size took into consideration ethical reasons related
to animal welfare in a pre-clinical study conducted with
drugs of abuse, such as the present one. The group
treated with MDMA received three doses of 5 mg/kg
MDMA salt, i.p., every 2 h (total cumulative dose of
15 mg/kg). MDMA was prepared at the day of use in a
concentration of 2.5 mg/mL in sterile NaCl 0.9 % (sa-
line solution). Control animals received saline solution
at the same schedule and using equivalent injection
volumes of treated animals. Rats’ temperature was
monitored and registered every 15 min for a total of
7 h, after the first dose. Food and water consumption,
as well as animal weight were evaluated before the first
injection and at the next day. Twenty-four hours fol-
lowing the first MDMA administration adolescent rats
were sacrificed.
Brain and organ tissue collection
Animals were anesthetized and euthanized with the
volatile anaesthetic, isoflurane. Before decapitation,
blood was collected from the inferior vena cava. Fol-
lowing sacrifice, brain areas (cerebellum, hippocampus,
frontal cortex and striatum) and peripheral organs
(liver, heart and kidneys) were collected. The collection
of the different brain regions was performed in agree-
ment to a rat brain atlas [29], and the dissection tech-
niques were conducted in accordance to a previous
work [30]. The brain and peripheral organs were also
weighted.
Brain tissue treatment
Samples of brain areas from the right hemisphere were
collected in RIPA buffer supplemented with protease
inhibitors [0.1 % sodium dodecyl sulphate, 1 % Triton
X-100, 0.5 % sodium deoxycholate, 150 mM NaCl,
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50 mM Tris, 1 mM sodium fluoride, 1 mM sodium
metavanadate, 0.25 mM phenylmethanesulfonyl fluoride
(PMSF), proteases inhibitor cocktail from Sigma, pH =
8.0]. Then brain samples were homogenized while kept
on ice using a sonicator (20 seconds, continuously) and
centrifugation followed (16,000 g, 15 min at 4 °C). The
supernatants were separated for the protein carbonyla-
tion and quinoprotein analysis. Meanwhile, brain sam-
ples obtained from the left side of each hemisphere were
placed in 5 % perchloric acid and homogenized in a
sonicator (20 seconds, continuously), while tubes were
kept on ice. Centrifugation was followed (16,000 g,
10 min at 4 °C), and the resulting supernatants separated
for ATP and glutathione determinations. The sample
pellets were stored for protein determination. All sam-
ples were frozen at −80 °C until further analysis.
Organ tissue treatment
Small sections (5 mm3) of liver (from different lobes),
heart (apex) and kidneys (including cortex and medulla)
were fixed during 24 h using a 4 % paraformaldehyde so-
lution in PBS, and further processed for qualitative
histologic analysis. A section of liver, heart and kidneys
was collected for caspases activity assay in caspase lysis
buffer (0.5 % Triton X-100, 25 mM HEPES, 5 mM mag-
nesium chloride, 1 mM EDTA, 5 mM dithiothreitol, and
1 mM PMSF, pH = 7.4). Another section was collected in
complete RIPA buffer supplemented with protease in-
hibitors, and homogenized using a sonicator (30 seconds,
continuously), while tubes were kept on ice. Centrifuga-
tion was followed (2376 g, 10 min at 4 °C) and the super-
natants were collected for the quinoprotein and protein
carbonylation determinations. Samples in caspase lysis
buffer or in RIPA buffer were stored at −80 °C until fur-
ther analysis. Another section of each organ was col-
lected and homogenized in an Ultra-Turrax (samples
diluted in 0.1 M potassium dihydrogen phosphate solu-
tion, pH = 7.4). One portion of homogenate was stored
at −20 °C for protein quantification. Other portion of
homogenate was added to perchloric acid 5 % solution
and centrifuged (16,000 g, 10 min at 4 °C). The resultant
supernatants were then stored for ATP and total gluta-
thione (GSHt) or oxidized glutathione (GSSG) biochem-
ical determinations. Samples for reduced glutathione
(GSH)/GSSG analysis were stored at −20 °C, meanwhile
those for ATP quantification were frozen at −80 °C.
Measurement of plasma biomarkers
The levels of aspartate aminotransferase (AST) and ala-
nine aminotransferase (ALT), as well as total creatine
kinase (CK) and creatine kinase-MB (CK-MB), were de-
termined in blood plasma as previously described by our
group [31]. The enzymatic assays were conducted
according to the manufacturer’s instructions in the ap-
paratus ABX Pentra 400 (Kyoto, Japan).
Assessment of ATP levels
ATP levels were quantified by a bioluminescent assay
using the luciferin-luciferase system, as described in de-
tail in previous works [26, 32]. The results are presented
in nmol of ATP per mg of protein.
Measurement of GSHt, GSH and GSSG
The GSHt or GSSG levels were evaluated by the 5,5′-
dithiobis(2-nitrobenzoic acid)-GSSG reductase recycling
assay, as previously we described in detail [26, 32]. GSH
levels were calculated by the equation: GSH = GSHt – 2
× GSSG. Levels of GSHt, GSSG and GSH were normal-
ized to the protein content (results presented in nmol
GSH per mg protein or nmol GSSG per mg protein).
Protein carbonylation assay
Protein carbonylation was determined as we previously
reported [33], with minor modifications. Samples
(0.1 mg protein/mL) reacted with 2,4-dinitrophenylhy-
drazine (0.2 μg) and were loaded into nitrocellulose
membranes (Hybond ECL, Amersham Pharmacia Bio-
tech) in a slot blot device. After washing steps, mem-
branes were exposed to the primary antibody (rabbit
polyclonal anti-DNP, 1:1000) overnight at 4 °C. Incuba-
tion at room temperature with the secondary antibody
(anti-rabbit IgG-peroxidase, 1:2000, 1 h) was followed.
Exposure to Clarity™ Western ECL Substrate (Bio-Rad,
CA, USA) was used to visualize membrane bands.
Digital images were obtained and treated with Molecular
Imager® ChemiDocTM XRS+ System (Bio-Rad, CA,
USA). Membranes were analysed with Image Lab Soft-
ware (Bio-Rad, CA, USA) and results expressed as % of
optical density control values.
Assessment of quinoproteins
The protein-bound quinones were determined using
nitrotetrazolium blue chloride/glycinate colorimetric
assay, as previously described [26]. For the assay, lysates
in RIPA buffer were used, and the reaction mixture of
brain samples contained 50 μg of protein, meanwhile
peripheral organs samples contained 25 μg of protein.
Histological tissue procedures
Sections of liver, heart, and kidneys were prepared, and
analysed, as previously described by our group [31]. Fol-
lowing fixation in 4 % paraformaldehyde and paraffin
embedding, sections with 5 μm were mounted on silane-
coated slides (Sigma, S4651-72EA), and stained with
hematoxylin/eosin following routine procedures. Sam-
ples were photographed and analysed in a light
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microscope (Carl Zeiss Imager A1 attached to a digital
camera AxioCam MRc 5, Oberkochen, Germany).
Assessment of caspases-3, -9 and -8 activities
A fluorescent assay for tissues was used to determine
each caspase activity in the liver, heart and kidneys of
the animals, as previously described by our group [31].
The following fluorescent peptide substrates were used:
Ac-DMQD-AMC, for caspase-3, Ac-IETD-AMC, for
caspase-8, and Ac-LEHD-AMC for caspase-9. Caspase
activity was expressed in fluorescent units per μg of pro-
tein (FU/μg protein).
Protein sample quantification
The protein content of samples in RIPA or caspase lysis
buffer was quantified using the DC Protein Assay kit
(Bio-Rad, CA, USA). For other samples, proteins were
quantified by the Lowry method [34].
Statistical analysis
Results in tables and graphics are presented as mean ±
standard deviation. Statistical analysis was conducted
using GraphPad Prism version 6 (GraphPad Software, La
Jolla California, USA). The Shapiro–Wilk normality test
was conducted before group comparison. For data where
two groups were compared, the t-test was used for a
normal distribution or the Mann-Whitney Rank Sum test
when data did not follow a normal distribution. Statistical
analysis of the temperature, included in Fig. 1, was
conducted by a two-way analysis of variance (ANOVA)
with repeated measurements, followed by Bonferroni
post-hoc test, once a significant p was obtained. Statistical
significance was accepted at p values less than 0.05.
Results
MDMA evoked hyperthermia, but no changes in body
weight, food or water intake
Three MDMA doses were given to the animals (each
dose 5 mg/kg i.p., every 2 h) and the first dose did not
cause significant changes in body temperature (Fig. 1).
After the second dose of MDMA, rats had a significantly
higher body temperature when compared to the control
group (p <0.0001). Temperature persisted significantly
higher for almost 2 h after the third dose in treated ani-
mals. The temperature of MDMA-treated animals never
surpassed 39 °C even after the third MDMA dose (Fig. 1).
The temperature was also measured 24 h post-MDMA
binge administration and no differences were observed
in the temperature among controls and MDMA-treated
rats (data not shown).
Recordings of body weight gain, food or water intake
before and 24 h after exposure showed no differences
among control and MDMA-treated rats (data not
shown). In fact, there was a slight decrease in the body
weight of animals in both groups, possibly as a result of
the animal stress due to the manipulation. The food
consumption was similar in both control and MDMA-
treated animals. However, there was a tendency for an
Fig. 1 Temperature monitoring of adolescent rats after exposure to three doses of NaCl 0.9 % i.p. (control) or 5 mg/kg MDMA i.p. (MDMA-treated)
during 7 h. Results in degrees Celsius (°C) are presented as mean ± standard deviation, from seven animals in each group. Statistical comparisons were
made using two-way ANOVA repeated measurements followed by the Bonferroni post hoc test (*p <0.05, **p <0.01, ***p <0.001 and ****p <0.0001
treatment vs. control)
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increased water intake in animals that received MDMA,
but it was not statistically significant (data not shown).
Liver, heart and kidneys weights were not changed
Each core organ (liver, heart, kidneys, and brain) had
their weight registered and the weight ratio of each
organ was taken to brain weight. No significant differ-
ences were observed between MDMA-treated rats and
the control group for all collected organs (Table 1).
MDMA decreased ATP content in the frontal cortex
Twenty-four hours after MDMA exposure, ATP levels
showed no significant changes in cerebellum, hippocam-
pus and striatum, as can be seen in Fig. 2a, b and d, re-
spectively. Importantly, there was a significant decrease
in the ATP content of the frontal cortex of the MDMA-
treated group (p = 0.007) (Fig. 2c).
No changes in oxidative stress related parameters in the
brain areas
There were no significant alterations in the levels of
GSHt, GSSG, GSH and GSH/GSSG ratio in the cerebel-
lum, hippocampus, frontal cortex, and striatum of
treated rats when compared to controls (Table 2).
Moreover, MDMA had no influence on quinoprotein
levels in the brain areas. In cerebellum, hippocampus,
frontal cortex and striatum no differences were found
between controls and MDMA-treated animals regarding
quinoprotein levels (Table 2).
The levels of protein carbonylation in the cerebellum,
hippocampus, frontal cortex and striatum are also pre-
sented in Table 2, and there were no significant alter-
ations in protein carbonyl levels in the four brain areas
of treated animals.
No changes in plasma AST, ALT, CK-MB and CK levels
The plasma levels of CK, CK-MB, AST and ALT were
measured 24 h after exposure as biomarkers of liver,
heart or muscle integrity (Table 3). There were no sig-
nificant differences in these parameters between control
and MDMA-treated animals. The ratio AST/ALT was
also calculated, but no significant differences among
groups were found (data not shown).
MDMA promoted vacuolization, oedema and vascular
congestion in the peripheral organs
The qualitative histologic examination of peripheral
organs (liver, heart and kidneys) of control and MDMA-
treated rats was performed by means of optical micros-
copy. Representative histological figures can be observed
in Fig. 3.
The control group showed a preserved liver tissue
structure (Fig. 3a). Livers of MDMA-treated rats pre-
sented a marked cellular vacuolization in the periportal
regions, and sinusoidal dilatation with periportal and
centrilobular vascular congestion (Fig. 3b). No necrotic
zones or interstitial inflammatory cell infiltration was
observed in either group.
In the histological analysis of the heart, both controls
(Fig. 3c) and MDMA-treated (Fig. 3d) animals revealed a
normal tissue organization without signs of necrosis or
interstitial inflammatory cell infiltration. MDMA exposed
animals presented random signs of cardiomyocyte oedema,
particularly in the sub-endocardic region (Fig. 3d).
The renal tissue organization remained preserved in
the control group (Fig. 3e). However, the MDMA-
treated group presented scattered interstitial oedema,
detected by the enlarged space between the tubular
structures, and signs of vascular congestion (Fig. 3f ). No
necrotic zones or interstitial inflammatory cell infiltra-
tion was observed in either group.
GSH homeostasis unaffected in the liver, heart, and
kidneys
The levels of GSHt, GSSG, GSH and GSH/GSSG ratio
in the liver, heart and kidneys in both groups are in-
cluded in Table 4. No differences were found for all
these parameters in the three organs, between control
and MDMA-treated animals.
ATP content was unchanged in the peripheral organs
ATP levels were measured in the liver, heart and kid-
neys, and no significant differences in the ATP content
were observed between control and MDMA-treated ani-
mals, as can be seen in Table 4.
Protein-bound quinones formation increased by MDMA in
the liver
In Fig. 4, the levels of protein-bound quinones (quinopro-
teins) in the liver, heart and kidneys of control and
MDMA-treated animals can be observed. There was a sig-
nificant increase in hepatic quinoprotein levels in the
MDMA-treated group (p = 0.039) (Fig. 4a). No differences
were found regarding this parameter in the heart or kid-
neys when comparing both groups (Fig. 4b and c).
Table 1 Organ weight in control and MDMA–treated groups
Control MDMA
Heart weight/Brain weight ratio 0.33 ± 0.03 0.32 ± 0.05
Kidneys weight/Brain weight ratio 0.69 ± 0.03 0.66 ± 0.07
Liver weight/Brain weight ratio 3.42 ± 0.17 3.15 ± 0.36
Liver weight/brain weight ratio, heart weight/brain weight ratio, and kidneys
weight/brain weight ratio of control and MDMA-treated rats. Results are pre-
sented as mean ± standard deviation, and were obtained from seven animals
in each group. The mean brain weight of control animals was 1.57 ± 0.04, and
of MDMA-treated was 1.63 ± 0.05. Statistical comparisons were made using the
t-test for the heart weight/brain weight ratio and the Mann-Whitney Rank Sum
test for the liver weight/brain weight ratio and kidneys weight/brain
weight ratio
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MDMA showed a tendency to increase protein
carbonylation in the kidneys
In Table 4 are presented the results of protein carbonyla-
tion in the liver, heart and kidneys in the two groups. No
significant differences were found in the levels of protein
carbonyls in the liver and heart between groups.
However, data showed a tendency for an increase
(p = 0.051) in protein carbonylation in the kidneys of
MDMA-treated rats, although not reaching statistical
significance.
Caspase-8 activity decreased in the liver, while caspase-3
and -9 activities remained unaltered
Data concerning the activities of caspase-3, -8 and -9 in
liver, heart, and kidneys in the two groups are presented
in Table 5. Caspase-8 activity significantly decreased in
the liver of MDMA-treated rats when compared to con-
trols (p = 0.038). No differences were found in the activ-
ity of this protease either in heart or kidneys. The
activities of caspase-3 and caspase-9 had no significant
alterations in all three organs following MDMA when
compared to the control group.
Discussion
In the present work, we studied the acute effects of a
moderate MDMA binge dose scheme (3 × 5 mg/kg,
every 2 h, i.p.) in an adolescent rat model. Using a dose
that does not evoke serotonergic neurotoxicity in adoles-
cent rats we did not observe any signs of brain oxidative
stress and the toxic effects occurred mainly in the per-
ipheral organs. The major findings were: 1) sustained
hyperthermic response after the second MDMA dose; 2)
decreased ATP levels in the frontal cortex; 3) no oxida-
tive stress related changes in the brain areas studied, as
no alterations were seen in GSH/GSSG ratio, quinopro-
tein and protein carbonylation levels; 4) signs of histo-
logical damage were seen in the liver, heart, but most
notoriously in the kidneys; 5) quinoproteins increased in
the liver of MDMA-treated animals.
Animals reproduce the MDMA-induced hyperthermia
seen in humans. Neurotoxic doses can promote core
body temperatures of 40 °C in rats [27, 35], once again
more related to an intensive abuser profile. In PND 40
rats 4 × 10 mg/kg, every 2 h, i.p., can evoke a robust
hyperthermia, reaching 2.5 °C above the control levels
[27]. In this study, MDMA promoted a significant in-
crease in adolescent rats’ body temperature, rendering a
mean increase of about 1 °C. Therefore, we proved that
lower MDMA doses do produce hyperthermia in adoles-
cent rats. Our dose scheme clearly more closely repro-
duces the human scenario, since human studies found
body temperature increases of about 1 °C in “ecstasy”
dance clubbers [36], thus rendering more reliable the ex-
trapolation to human adolescents.
Fig. 2 ATP content in the cerebellum (a), hippocampus (b), frontal cortex (c) and striatum (d) after MDMA administration to adolescent rats.
Results, in nanomol per mg of protein (nmol/mg protein), are presented as mean ± standard deviation, and were obtained from seven animals in
each group. Statistical comparisons were made using the t-test (**p <0.01 treatment vs. control)
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MDMA abuse promotes several physiological changes,
and, for that reason, we also evaluated body weight gain,
as well as water and food consumption. In the literature,
the cardiovascular changes and anorectic actions of
amphetamines and MDMA are well described [2]. A de-
crease in body weight was found in both groups of ani-
mals with similar levels, possibly a consequence of stress
evoked by animal handling throughout the experiment.
However, water intake slightly increased in MDMA-
treated animals in the next 24 h following exposure,
most likely due to MDMA-induced hyperthermia. Our
acute protocol neither evoked slower weight gain nor
animal dehydration, which is seen in protocols of animal
MDMA exposure during several days [37]. Therefore, it
appears that dehydration has not an important role in
our overall results.
Hyperthermia is a well-known important element in
MDMA-evoked neurotoxic actions to animals [16], and
drugs that prevent MDMA-induced hyperthermia pro-
tect against MDMA-induced serotonergic neurotoxicity
[35, 38]. Furthermore, studies in vitro in neuronal cul-
tures revealed that the MDMA-induced neurotoxic ef-
fects are potentiated by hyperthermia [26, 39]. A report
using adult (10 week old) Wistar rats that received the
same MDMA binge scheme of our study, revealed that
under normal ambient temperature (21.5 °C) animals
showed an hyperthermic response and long-term 5-HT
depletion, which were blocked when the drug was ad-
ministrated under low environmental temperature (15 °
C) [16]. Therefore there is a tight relation between body
temperature and MDMA serotonergic neurotoxicity
[16]. Moreover, we have shown that our MDMA regi-
men (3 × 5 mg/kg, every 2 h, i.p.) in adolescent (PND
40) Wistar rats did not promote serotonergic neurotox-
icity 7 days after MDMA exposure (manuscript in prep-
aration). Altogether, our results show that hyperthermia
per se is not the triggering factor for serotonergic tox-
icity or to other neurotoxic actions. Nevertheless, the
hyperthermia induced by MDMA certainly potentiates
the toxicity found in the brain and most importantly in
the peripheral organs.
Despite the absence of serotonergic neurotoxicity, we
sought to study other markers of brain toxicity, namely
energetic status and oxidative stress parameters. It is
Table 2 Effect of MDMA administration in oxidative stress
related parameters in the four brain areas
Parameter Control MDMA
Hippocampus
GSHt (nmol/mg protein) 21.17 ± 1.22 22.87 ± 3.46
GSH/GSSG ratio 50.30 ± 12.72 50.26 ± 19.37
GSSG (nmol/mg protein) 0.42 ± 0.09 0.41 ± 0.18
GSH (nmol/mg protein) 20.33 ± 1.37 22.05 ± 3.72
Quinoprotein (OD/mg protein) 6.01 ± 0.78 6.09 ± 0.71
Protein carbonylation (% of control) 100.00 ± 28.69 88.01 ± 12.51
Frontal cortex
GSHt (nmol/mg protein) 18.60 ± 1.78 17.93 ± 1.70
GSH/GSSG ratio 61.44 ± 10.67 68.60 ± 18.71
GSSG (nmol/mg protein) 0.30 ± 0.05 0.27 ± 0.07
GSH (nmol/mg protein) 18.00 ± 1.77 17.39 ± 1.67
Quinoprotein (OD/mg protein) 5.54 ± 0.70 5.73 ± 0.50
Protein carbonylation (% of control) 100.00 ± 11.80 101.15 ± 10.18
Striatum
GSHt (nmol/mg protein) 20.70 ± 6.14 20.49 ± 4.68
GSH/GSSG ratio 47.49 ± 16.60 56.76 ± 14.98
GSSG (nmol/mg protein) 0.45 ± 0.22 0.35 ± 0.04
GSH (nmol/mg protein) 19.79 ± 5.88 19.78 ± 4.69
Quinoprotein (OD/mg protein) 5.76 ± 0.20 5.78 ± 0.15
Protein carbonylation (% of control) 100.00 ± 53.98 108.84 ± 45.81
Cerebellum
GSHt (nmol/mg protein) 13.32 ± 0.69 12.34 ± 2.80
GSH/GSSG ratio 25.20 ± 6.52 28.77 ± 12.21
GSSG (nmol/mg protein) 0.51 ± 0.12 0.47 ± 0.21
GSH (nmol/mg protein) 12.29 ± 0.80 11.40 ± 2.67
Quinoprotein (OD/mg protein) 5.93 ± 0.42 5.95 ± 0.29
Protein carbonylation (% of control) 100.00 ± 27.94 95.43 ± 19.88
Total glutathione (GSHt), oxidized glutathione (GSSG), reduced glutathione (GSH),
GSH/GSSG ratio levels, quinoprotein levels and protein carbonylation in
hippocampus, frontal cortex, striatum and cerebellum of adolescent rats. Data of
GSHt, GSSG and GSH levels, in nanomol permg of protein (nmol/mg protein), and
the GSH/GSSG ratio are presented as mean± standard deviation, and were
obtained from six to seven animals in each group. Statistical comparisons were
made using the t-test for GSHt and GSH levels in hippocampus, frontal cortex and
striatum, GSSG levels in cerebellum, hippocampus and frontal cortex, and GSH/
GSSG ratio levels in frontal cortex and striatum; the Mann-Whitney Rank Sum test
was used for GSHt and GSH levels in cerebellum, GSSG levels in striatum, and GSH/
GSSG ratio levels in cerebellum and hippocampus. Results of quinoprotein levels, in
optical density permg of protein (OD/mg protein), and protein carbonylation, in
percentage of controls (% of control), are presented as mean± standard deviation,
and were obtained from seven animals in each group. Statistical comparisons were
made using t-test for the quinoprotein levels in cerebellum and striatum and
protein carbonylation in cerebellum, hippocampus and frontal cortex; and
Mann-Whitney Rank Sum test for quinoprotein levels in hippocampus and frontal
cortex, and for protein carbonylation in striatum
Table 3 Effect of MDMA administration in plasma AST, ALT, CK-
MB and CK levels
Control MDMA
AST (U/L) 39.14 ± 17.53 45.71 ± 19.44
ALT (U/L) 25.00 ± 2.00 28.57 ± 3.82
CK (U/L) 202.57 ± 76.80 200.29 ± 75.54
CK-MB (U/L) 340.14 ± 138.90 305.86 ± 132.91
Plasma levels of total creatine kinase (CK), creatine kinase-MB (CK-MB), aspar-
tate aminotransferase (AST) and alanine aminotransferase (ALT) of control and
MDMA-treated rats. Results of CK, CK-MB, AST and ALT plasma levels are pre-
sented as mean ± standard deviation, and were obtained from six to seven ani-
mals in each group. Statistical comparisons were made using the t-test for CK,
CK-MB and AST levels, and the Mann-Whitney Rank Sum test for ALT levels
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important to know whether doses that do not cause de-
pletion of monoamines can elicit other toxic brain
changes. Several studies found transient changes in ATP
brain levels following amphetamines exposure, namely
MDMA or methamphetamine (METH). In fact, amphet-
amines are known to promote changes in tricarboxylic
acid cycle’s enzymes function, inhibition of the com-
plexes in mitochondrial electron transport chain and
overall interference with mitochondrial dynamics [40]. A
binge dose regimen of MDMA (4 × 10 mg/kg, every 2 h,
i.p.) with a total dose of 40 mg/kg found decreases in
the ATP levels in the striatum at time-points 1, 12 and
24 h, as well as in the hippocampus 12 h after MDMA
exposure [41]. A single METH dose of 5 mg/kg, i.p.,
caused a decline in ATP brain content in adolescent
Wistar rats (4 week old) 30 min after administration
[42]. The same authors also found that ATP brain levels
returned to control values 24 h following exposure to
the single METH dose [42]. Most likely there is a pos-
sible transitory effect in brain ATP levels caused by
MDMA, and the time frame may disclose that short pe-
riods following exposure a decrease in ATP levels occurs,
meanwhile longer periods following exposure ATP brain
levels can recover. Of note that only the frontal cortex
area showed a decrease in the ATP levels in the present
study. The involvement of this area in both memory and
decision-making is widely known, however it is unclear
whether this event is related with the impairment in
memory and learning abilities seen in young animals ex-
posed to MDMA [7, 8]. Importantly, in humans, “ec-
stasy” use was related to altered brain activity patterns
during associative learning in the left dorsolateral
Fig. 3 Optical micrographs of tissue sections stained with hematoxylin/eosin. a and b Photos of liver sections from control (a) and MDMA-treated rats (b).
MDMA-treated rats showed sinusoidal dilatation (green arrows) with a marked cellular vacuolization in the periportal regions. c and d Photos from heart
sections of controls (c) and MDMA-treated rats (d). In d scattered cardiomyocytes with signs of intracellular oedema (yellow arrows) can be observed, as
identified by the reduced cytoplasmic staining. e and f Photos of kidneys sections from controls (e) and MDMA-treated rats (f). In f a slight interstitial
oedema (blue arrows), detected by the enlarged space between the tubular structures, can be observed
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prefrontal cortex [13], an effect that we speculate to be
related to MDMA-induced energetic impairment in the
frontal cortex. More investigation is needed in adoles-
cent animals to confirm the long-lasting effects of am-
phetamines in ATP brain levels.
The metabolism of MDMA is a known triggering factor
for the toxicity of this drug. The MDMA metabolites are
highly reactive and can evoke oxidative stress [1]. Several
studies showed that MDMA metabolites promote neuro-
toxic effects to laboratory animals [43, 44]. Moreover,
MDMA metabolites, N-methyl-α-methyldopamine (N-
Me-α-MeDA, 3,4-dihydroxymethamphetamine, HHMA)
and α-methyldopamine (α-MeDA, 3,4-dihydroxyampheta-
mine, HHA), induced neuronal death in cultured cells [26,
39, 45]. N-Me-α-MeDA and α-MeDA are important
MDMA metabolites that can be oxidized into ortho-
quinones, and that enter a redox cycle-eliciting oxidative
stress [1]. Moreover, thioether MDMA metabolites were
shown to promote depletion of neuronal GSH and the
formation of quinoproteins in cultured neurons [26], and
the mixture of MDMA and its metabolites were shown
to impair mitochondrial fusion/fission equilibrium and
trafficking in cultured neurons [46]. Catechol MDMA me-
tabolites were also shown to promote toxicity to cardio-
myocytes [17] and to hepatocytes [47] in vitro. There are
other contributing factors for MDMA-induced oxida-
tive stress, including monoamine neurotransmitters
metabolism by monoamine oxidase [27], and nitric
oxide formation leading to damaging reactive nitrogen
species [1].
Our paradigm of MDMA exposure elicited no oxida-
tive stress related changes in the adolescent rat brain.
Other studies reported decreases in glutathione levels
[48] and increases in protein carbonylation [27] in the
rat brain after MDMA exposure. Major differences be-
tween the previously mentioned studies and the current
study are the use of higher doses, older animals, and dif-
ferent time-points at measurements. The lack of changes
in brain oxidative stress parameters following MDMA-
induced hyperthermia confirms that hyperthermia in-
duction per se is not a guarantee for MDMA-evoked
brain oxidative stress.
Regarding the oxidative stress related parameters eval-
uated in the liver, heart, and kidneys, we could only find
an increase in quinoproteins in the liver following
MDMA exposure. In fact, MDMA metabolism is pri-
marily hepatic, and, as previously mentioned, promotes
the formation of catechol metabolites that can generate
protein-bound quinones. Moreover, in rat hepatocytes,
catechol MDMA metabolites promoted ortho-quinones
formation and oxidative stress [47]. The increase in liver
quinoprotein formation possibly reflects the contribu-
tion of MDMA metabolism and the formation of react-
ive metabolites, and reveals the higher susceptibility of
the liver to MDMA-evoked toxicity.
Using higher doses and older animals, others reported
decreases in glutathione levels. Following administration
of a high MDMA dose in a total of 160 mg/kg (20 mg/
kg, i.p., 2 daily doses for 4 days), authors found de-
creases in GSH levels in the rat liver 3 and 6 h following
MDMA, which were recovered after 7 days [20, 22]. The
heart of rats exposed to MDMA in a dose of 20 mg/kg,
i.p., showed a reduction in total GSH levels at the 6 h
time-point [22]. The fact that our low MDMA binge
dose did not elicit changes in GSH levels in the
Table 4 Effect of MDMA administration in oxidative stress




GSHt (nmol/mg protein) 9.66 ± 1.30 9.53 ± 1.70
GSH/GSSG ratio 17.62 ± 7.38 15.86 ± 5.93
GSSG (nmol/mg protein) 0.53 ± 0.14 0.59 ± 0.23
GSH (nmol/mg protein) 8.60 ± 1.43 8.35 ± 1.46
Protein carbonylation (% of control) 100.00 ± 13.15 98.94 ± 11.50
ATP (nmol/mg protein) 0.63 ± 0.20 0.60 ± 0.27
Kidneys
GSHt (nmol/mg protein) 2.25 ± 0.38 1.93 ± 0.60
GSH/GSSG ratio 37.58 ± 11.26 32.39 ± 11.29
GSSG (nmol/mg protein) 0.06 ± 0.02 0.06 ± 0.01
GSH (nmol/mg protein) 2.12 ± 0.34 1.82 ± 0.60
Protein carbonylation (% of control) 100.00 ± 12.55 137.26 ± 37.28
ATP (nmol/mg protein) 1.75 ± 0.62 1.43 ± 0.57
Liver
GSHt (nmol/mg protein) 19.31 ± 1.96 18.51 ± 2.61
GSH/GSSG ratio 31.46 ± 9.22 28.68 ± 4.46
GSSG (nmol/mg protein) 0.60 ± 0.13 0.62 ± 0.14
GSH (nmol/mg protein) 18.10 ± 2.04 17.28 ± 2.38
Protein carbonylation (% of control) 100.00 ± 27.83 102.61 ± 23.37
ATP (nmol/mg protein) 1.60 ± 0.84 1.69 ± 0.38
Total glutathione (GSHt), oxidized glutathione (GSSG), reduced glutathione (GSH),
GSH/GSSG ratio levels, protein carbonylation and ATP levels in heart, kidneys and
liver of control and MDMA-treated adolescent rats. Results of GSHt, GSSG, and GSH
levels, in nanomol per mg of protein (nmol/mg protein), and the GSH/GSSG ratio
are presented as mean ± standard deviation, and were obtained from six to seven
animals. Statistical comparisons were made using the t-test for GSHt, GSSG, GSH
levels in the heart, kidneys and liver, and the GSH/GSSG ratio in the liver; and the
Mann-Whitney Rank Sum test for the GSH/GSSG ratio levels in the heart and
kidneys. Results of protein carbonylation, in percentage of controls (% of control),
are presented as mean ± standard deviation, and were obtained from six to seven
animals in each group. Statistical comparisons were made using the t-test for the
protein carbonylation in the heart and liver, meanwhile the Mann-Whitney Rank
Sum test showed in the kidneys a tendency for a change in protein carbonylation
(p= 0.051 treatment vs. control). Results of ATP levels, in nmol per mg of protein
(nmol/mg protein), are presented as mean ± standard deviation, and were obtained
from seven animals in each group. Statistical comparisons were made using the
t-test for the ATP levels in the heart and kidneys, and the Mann-Whitney Rank Sum
test for the ATP levels in the liver
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peripheral organs 24 h following exposure, reveals that
GSH levels might not have been affected or that GSH
could decrease at early times of exposure but then re-
covered. Overall, moderate MDMA doses in rats do not
seem to elicit long lasting GSH and ATP decreases to
the peripheral organs.
Protein carbonylation increase was observed in the rat
liver 12 h following two doses of MDMA 10 mg/kg
administered orally with a 24 h interval [23]. Enhanced
carbonylation in the kidney has been associated with the
development of hypertension and kidney disease [49]. Im-
portantly, MDMA administration was shown to increase
blood pressure in humans [36], as well as in laboratory an-
imals [4]. In accordance, both the histological damage and
the trend for protein carbonylation increase that we found
in the kidneys reveal that this organ may be highly prone
to damage following MDMA.
Vascular alterations that we observed in the three
studied organs, including vascular congestion, after ex-
posure to MDMA have been associated to the MDMA-
elicited hyperthermic response [50]. In fact, other studies
reported vascular lesions in the peripheral organs as a
consequence of hyperthermia [51, 52]. The exposure of
Wistar rats to high temperature environments was pre-
viously shown to result in several vascular lesions in the
heart, liver, kidneys, and lungs of animals that can
Fig. 4 Quinoprotein levels in liver (a), heart (b) and kidneys (c) of control and MDMA-treated adolescent rats. Results, in optical density per mg of
protein (OD/mg protein), are presented as mean ± standard deviation, and were obtained from seven animals in each group. Statistical compari-
sons were made using the t-test for the quinoprotein levels in the liver and kidneys and the Mann-Whitney Rank Sum test for the quinoprotein
levels in the heart (*p <0.05 treatment vs. control)
Table 5 Effect of MDMA administration in caspase-3, -9 and -8
activities in the three peripheral organs
Parameter (FU/μg protein) Control MDMA
Heart
Caspase-3 0.44 ± 0.05 0.42 ± 0.06
Caspase-9 0.09 ± 0.02 0.11 ± 0.05
Caspase-8 0.48 ± 0.08 0.47 ± 0.11
Kidneys
Caspase-3 0.59 ± 0.08 0.56 ± 0.06
Caspase-9 0.90 ± 0.18 0.79 ± 0.11
Caspase-8 0.66 ± 0.09 0.62 ± 0.07
Liver
Caspase-3 1.19 ± 0.31 1.12 ± 0.31
Caspase-9 0.90 ± 0.07 0.86 ± 0.13
Caspase-8 1.00 ± 0.06 0.93 ± 0.20*
Caspase-3, -8 and -9 activities in the heart, kidneys and liver of adolescent rats
that received either saline or MDMA. Results of caspase-3, -8 and -9 activities,
in fluorescent units per μg of protein (FU/μg protein), are presented as mean
± standard deviation, and were obtained from seven animals in each group.
Statistical comparisons were made using the t-test for the caspase-3 activity in
the liver, heart and kidneys and caspase-8 and -9 activities in the heart and
kidneys, and the Mann-Whitney Rank Sum test for the caspase-8 and -9 activ-
ities in the liver (*p <0.05 treatment vs. control)
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possibly lead to functional organ failure [52]. Those ef-
fects were similar to the signs of damage observed in
our study. Halpin and co-workers reported morpho-
logical damages in the liver of rats 24 h after the treat-
ment with METH. The referred morphological changes
were prevented when the hyperthermic response in-
duced by the treatment with METH was blocked, sug-
gesting that liver damage is possibly a consequence of
METH-induced hyperthermia [51]. Therefore, it can be
postulated that the hyperthermic response observed in
our experiment may have contributed to the observed
histological alterations. The liver may be an organ with
greater susceptibility to MDMA toxicity as indicated not
only by the tissue damage, but also because it was the only
to show an increase in quinoprotein formation. Of note,
that one of the most frequently reported damage promoted
by MDMA in humans is hepatotoxicity [18, 24, 25]. In fact,
MDMA liver metabolism and hyperthermia may cooperate
to render the liver very vulnerable to damage.
The lack of changes in the plasma levels of AST, ALT,
CK and CK-MB after MDMA exposure corroborates the
absence of necrosis in the heart and liver. Moreover, the ab-
sence of caspase activity increase in the organs proves the
lack of severe damage to the tissues, given that caspases are
important effectors of the apoptotic pathway [53]. The not-
able exception of caspase-8 activity in the liver, which re-
vealed a significant decrease in MDMA-treated rats, might
be related to a repression of genes related to apoptosis. The
inhibition of caspase-8 activity has been observed in hepatic
cells through nitric oxide signalling [54]. In cultured rat
striated cardiac myocytes there was a repression of caspase-
1 and caspase-8 genes following exposure to MDMA [55].
Using higher doses (20 mg/kg, i.p., twice daily during 4 days,
in a total dose of 160 mg/kg), hepatic necrosis with inflam-
matory infiltrate around hepatic vein and increases in AST
levels were found at the 6 h time-point [20]. The heart is
particularly susceptible to oxidative stress-related injuries
and amphetamines like MDMA evoke cardiotoxicity [56].
Exposure of adult Sprague-Dawley rats (300 g) to MDMA
binges (9 mg/kg, intravenous twice daily, for 4 days), a
neurotoxic dose regimen, showed that MDMA promoted
cardiac foci of inflammatory infiltrates, the presence of nec-
rotic cells and/or disrupted cytoarchitecture [4]. Another
report in adult rats (200–250 g) after a single MDMA dose
(20 mg/kg, i.p.) showed myocardial necrosis and following
16 h the heart exhibited macrophagic monocytes around
the necrotic myocardial cells [22]. Our study used lower
MDMA doses in adolescent rats and drug exposed hearts
showed a particular vulnerability of the myocytes from the
sub-endocardic region. Reports from MDMA users follow-
ing fatalities describe major organ changes, including
necrosis, oedema and inflammation [1, 24, 25]. These im-
portant human findings report a rather extreme scenario
following the course of MDMA intoxication. Our report
more reliably reproduces the hyperthermia seen in human
abusers and organ changes might be more similar to
those seen in adolescents.
Conclusions
MDMA moderate doses, more close to those used by
human adolescents, do not elicit in adolescent rats oxidative
stress related changes in the brain. Meanwhile, ATP levels
in frontal cortex were decreased following MDMA. MDMA
treatment in adolescent rats promoted morphological tissue
alterations in the heart, kidneys, and liver, as well as rises in
liver quinoproteins. New studies are required to assess the
impact of moderate MDMA doses in adolescent animals to
verify whether these brain and peripheral organ changes are
long-lasting and may be reflected later during adulthood.
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